Purdue Pharma and OxyContin
OxyContin launched in 1996 with a story: continuous pain relief, lower abuse potential than older opioids because of its time-release design. Prescribing surged. So did addiction. By the time federal prosecutors announced Purdue Pharma's guilty pleas, the company's marketing claims had been dissected in warehouses of litigation exhibits.
The Marketing Machine
Sales reps were trained and incentivized to push OxyContin hard. Prescribers who wrote high volumes got attention. Messaging minimized addiction risk in ways prosecutors later called fraudulent. The time-release narrative became a shield that street reality and reformulation debates eventually cracked.
This was not a secret lab cult. It was pharmaceutical capitalism with a DEA schedule and a sales force—documented in emails, call notes, and settlement agreements.
Courtrooms as Archive
DOJ criminal resolutions, state AG suits, and bankruptcy court fights turned Purdue into one of the best-documented corporate harm cases of the twenty-first century. The Sackler family's owners' role, wealth extraction, and immunity fights became a second public narrative alongside the pill itself.
Public-health researchers chart overlapping waves: prescription opioids, then heroin, then fentanyl. Purdue sits at the front of that sequence without monopolizing every later death. Multiplicity of manufacturers and distributors appears throughout the dockets.
What Not to Paste On
Internet layers sometimes cast OxyContin as intentional population culling or as proof of a single cabal spanning every pharmacy board. Court records support deception for profit and reckless disregard—already a damning charge. They do not require cartoon villain metaphysics. Compare Prohibition-era poisoned alcohol elsewhere in the Archive: state or corporate harm via chemical markets is an old American genre.
Settled Spine
Purdue misled about OxyContin's risk profile, pleaded guilty, and remains central in opioid-crisis historiography. Readers chasing "who else knew" will find plenty of physicians, wholesalers, and regulators in the same story. Readers chasing depopulation prophecies will leave the exhibit rooms empty-handed.
Settlements Without Absolution
Guilty pleas and bankruptcy plans redistribute money; they do not rewind overdose curves. Public-health agencies still chart polysubstance deaths that outgrew any single pill's patent life. Purdue is a necessary chapter, not a full encyclopedia of opioid supply.
Corporate document archives produced in discovery are now historical sources as much as FDA labels ever were. Read them as you would FRUS: interested authors, invaluable paper.
